ShineWing Certified Public Accountants (Special General Partnership)
Reply to the Inquiry Letter Regarding Wuhan Zhongyuan Huadian Technology Co., Ltd.'s Application for Issuing Shares to Specific Objects (Revised Draft)
XYZH/2026BJAA12F0072
Wuhan Zhongyuan Huadian Technology Co., Ltd.
Shenzhen Stock Exchange:
ShineWing Certified Public Accountants (Special General Partnership) (hereinafter referred to as "ShineWing" or "we") is the reporting accountant for Wuhan Zhongyuan Huadian Technology Co., Ltd.'s (hereinafter referred to as "Zhongyuan Shares", "the Company", or "the Issuer") application for issuing shares to specific objects. We have prudently reviewed the issues or matters that the China Securities Regulatory Commission requested us to verify in the Inquiry Letter [2026] No. 020016 issued by the Shenzhen Stock Exchange on February 28, 2026 (hereinafter referred to as the "Inquiry Letter"). It is the responsibility of Zhongyuan Shares' management to provide true and complete relevant information and to respond truthfully to the questions and matters raised in the Inquiry Letter. Our responsibility is, based on our audit work, to verify the relevant information and responses provided by the Issuer and to express our audit opinion on the issues or matters that the Inquiry Letter requires us to verify.
Unless otherwise specified, the abbreviations and definitions used in this reply to the Inquiry Letter are consistent with those in the "Prospectus for Wuhan Zhongyuan Huadian Technology Co., Ltd.'s 2025 Annual Issuance of A Shares to Specific Objects" (hereinafter referred to as the "Prospectus"). If there are discrepancies in the sum of some subtotals or figures due to rounding, it is due to rounding.
We now reply to the issues or matters that the Inquiry Letter requires us to verify, item by item:
The content of this reply is presented in the following font:
Inquiry Letter Question | Reply to the Inquiry Letter Question
---|---
Bold, Bold | Song Style
Table of Contents
Inquiry Letter Reply (Continued) | XYZH/2026BJAA12F0072
Question 1: ... 3
Question 2: ... 78
Question 1:
- During the reporting periods, the Company's operating revenue was RMB 44,280.76 million, RMB 44,808.54 million, RMB 55,369.27 million, and RMB 41,534.97 million, respectively. Revenue from medical information technology business was RMB 7,456.04 million, RMB 3,097.16 million, RMB 1,831.73 million, and RMB 1,355.20 million, respectively, showing a downward trend year by year. During the reporting periods, the Company's comprehensive gross profit margin was 46.10%, 47.34%, 46.97%, and 50.26%, respectively, which is higher than the average level of comparable companies in the same industry (33.70%, 35.47%, 35.67%, and 34.51%). The gross profit margin of the Company's comprehensive energy service projects was 30.96%, 21.38%, 18.89%, and 12.14%, showing an overall downward trend. The gross profit margin of the medical information technology projects was 24.10%, 25.89%, 5.23%, and 45.32%, showing significant fluctuations.
During the reporting periods, the Company's sales expenses were RMB 5,996.87 million, RMB 5,609.04 million, RMB 6,188.62 million, and RMB 3,355.57 million, respectively, mainly composed of employee compensation and business entertainment expenses. During the reporting periods, the revenue from the top five customers included in the consolidated statements was RMB 25,450.31 million, RMB 32,668.37 million, RMB 41,370.34 million, and RMB 31,072.59 million, accounting for 57.47%, 72.91%, 74.72%, and 74.81% of the operating revenue, respectively. The top five customers include some hospital clients. During the reporting period, there were some clients that overlapped with suppliers. The total purchase amount was RMB 679.62 million, RMB 389.4 million, RMB 1,052.03 million, and RMB 740.98 million, respectively. The total sales amount was RMB 2,901.35 million, RMB 2,291.65 million, RMB 2,611.42 million, and RMB 2,253.27 million, respectively.